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Tuberculosis continues to be a worldwide public-health pro-
blem, with an estimated 90 million new cases and 30 million
deaths during the last decade of the 20th century [1]. It has been
an ever-present health threat in developing countries. At the
same time, it has been increasing in Europe and the USA
following the emergence of AIDS in the world [2]. The
prevalence of tuberculosis in Turkey is 0.35%, and 30 000–
40 000 new cases are being reported every year [3]. An esti-
mated 2 billion people are currently infected with Mycobacterium
tuberculosis and Mycobacterium intracellulare complex throughout
the world [4]. The rates of morbidity and mortality are also
rising as a result of multidrug-resistant strains [5].
The diagnosis of mycobacterial diseases depends upon iden-
tifying the infecting organism in the secretion or tissues.
However, there are several limitations of this method. One is
that Mycobacterium tuberculosis is usually present in undetectable
numbers (for smear 5 103 to 5 104 bacilli/mL, and for
culture 10–100 bacilli/mL), so that it is recognized for the
most part in advanced cases [6]. Second, most mycobacteria are
slow-growing organisms and require long periods of time to
culture, even if the most advanced techniques are used [6,7].
Third, negative smears are usually obtained until cavities form
[8]. Thus, a fast, easy and reliable method was needed for the
diagnosis of tuberculosis. Among several serologic techniques, it
has been concluded that enzyme immunoassay (EIA) is a
sensitive, reliable, simple and rapid method [6]. Several purified
antigens, such as 38-kDa protein, 85A antigen, lipoarabino-
mannan, plasma membrane antigen, antigen 5 and antigen 60
(A60), have been used for the serodiagnosis of tuberculosis
[8–12]. This study was undertaken to evaluate the usefulness
of the EIA method using A60 antigen for the diagnosis of
different forms of tuberculosis in Turkish patients.
Serum samples were collected from four groups of patients
and the control group. Sera from active tuberculosis patients
were collected before chemotherapy, and kept at 70 8C until
the EIA procedure.
Group 1 consisted of 112 patients (74 male, 38 female) with a
mean age of 36.32 12.25 years, who were diagnosed as having
active lung tuberculosis by positive smear and/or culture
and clinical and radiologic findings. They were all anti-HIV
negative.
Group 2 consisted of 40 patients (29 male, 11 female) with a
mean age of 59.47 13.36 years, with the diagnosis of inactive
lung tuberculosis by radiologic findings and patient history.
Three of the patients had a history of tuberculosis during the
previous 2 years, and 26 of them had a history of tuberculosis
before that period. Eleven of 40 patients had no tuberculosis
history but had findings related to a previous infection in their
chest X-rays. None of their sputum smears and cultures were
positive.
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Group 3 consisted of 21 patients (9 male, 12 female) with a
mean age of 36.0 14.37 years, diagnosed as having miliary
tuberculosis by radiologic findings and positive cultures of
various specimens (four sputum, one bronchoalveolar lavage,
two transbronchial, one larynx, one liver, three lymph node
biopsies). All cases had scattered miliary densities on their chest
X-rays. Two patients also had cavities in their radiographs. They
were all anti-HIV negative.
Group 4 consisted of 41 patients (17 female, 24 male) with a
mean age of 34.18 12.45 years, with various lung diseases
other than tuberculosis. Among these patients, 21 had lung
tumors, while seven, four and four of them had bronchiectasis,
chronic obstructive pulmonary disease/chronic bronchitis and
pneumonia, respectively. The diagnoses of the rest of the cases
were: bronchial asthma (one), sarcoidosis (one), idiopathic
hemoptysis (one), lung fibrosis (one) and asbestosis (one).
Group 5 consisted of 38 heathy individuals (19 male, 19
female) with a mean age of 36.86 14.43 years.
The serum samples were kept at 70 8C until tested. Sera of
all the patients and healthy individuals were searched for IgG
and IgM antibodies against A60 by micro EIA (Eurospital spa,
Trieste, Italy). IgA antibodies were only investigated in the sera
of 135 patients and in all healthy individuals with the same
method, according to the manufacturer’s instructions. Calibra-
tors were used in the IgG and IgA tests, so that the results were
quantitated. For the IgM test, the results were given as –, , þ.
The cut-off points of EIA for each antibody were calculated
from the results obtained with sera from the healthy group using
the following formula: the mean value obtained from the
healthy control group 2 standard deviation.
The sensitivity, specificity and predictive values were esti-
mated with the Epi Info Version 6 Program [13]. Statistical
significance was determined by the chi-squared test and chi-
squared test with Fisher’s correction with the SPSS Program
6.0 [14].
The cut-off value for IgG EIA was calculated as 2 EU (EIA
units). The numbers of positive cases for IgG in all groups are
shown in Table 1. A comparison of the groups, according to the
positivity rates of IgG, revealed a statistical difference
(w2¼ 42.50, P¼ 0.0000). Patients with active tuberculosis
showed a significantly higher positivity rate of IgG than
healthy individuals and the patients with lung diseases other
than tuberculosis (w2¼ 18.55, P¼ 0.00002, and w2¼ 27.31,
P¼ 0.00000, respectively). At the same time, statistically
important differences were observed between the active and
inactive tuberculosis groups (w2¼ 9.68, P¼ 0.00186). The
sensitivity, specificity and positive predictive and negative pre-
dictive values for IgG are shown in Table 2.
The number of cases positive for anti-A60 IgM in each group
are shown in Table 1. A statistical difference was observed
when the positivity rates of all the groups and groups 1 and
4 and 5 were compared (w2¼ 49.54, P¼ 0.0000, w2¼ 15.32,
P¼ 0.00009, and w2¼ 21.59, P¼ 0.00000, respectively). The
number of positive cases in the active tuberculosis group was
significantly higher than the number of positive cases in the
inactive tuberculosis group (w2¼ 17.21, P¼ 0.00003). The
sensitivity, specificity and positive predictive and negative pre-
dictive values for IgG are shown in Table 2.
A60 IgA was detected in 50 of 64 cases of active and 14 of
nine cases of miliary tuberculosis (Table 1). A statistical differ-
ence was detected between the positivity rates of all groups
(w2¼ 56.93, P¼ 0.0000). There was also a statistically signifi-
cant difference between groups 1 and 4 and 1 and 5 (w2¼ 35.21,
P¼ 0.00067; w2¼ 47.11, P¼ 0.00000). The positivity rates of
groups 1 and 2 were also compared for IgA, and a statistically
important difference was observed (w2¼ 17.33, P¼ 0.00003).
The sensitivity, specificity and positive predictive and negative
predictive values for IgG are shown in Table 2.
There was no statistical difference between the antibody
responses of the smear-negative and smear-positive cases of
groups 1 and 3 (P> 0.05). There was also no statistically
important difference between the culture-negative and cul-
ture-positive cases of group 3 (P> 0.05).
The development of mycobacterium infections entails a
strong interaction of components of mycobacteria and the
immune system of the host [15]. These mycobacterial compo-
nents and the antibodies against them are valuable for the
diagnostic assays of tuberculosis. One of the best known anti-
gens is A60, which is the major heat-stable component of
tuberculin and protein purified derivative (PPD).
The sensitivity and specificity for IgG against A60 in pul-
monary tuberculosis cases were found to be 36–91% and 68–
98%, respectively [16–24]. In this study, we found the sensitivity
and specificity values for IgG A60 to be 53.6% and 94.7%,
Table 1 The positivity rates for IgG, IgMand IgA for the groups
Group number n IgG positive (%) IgM positive (%) n IgA positive (%)
1 112 60 (53.6) 49 (43.8) 64 50 (78.1)
2 40 10 (25.0) 3 (7.5) 40 15 (37.5)
3 21 10 (47.6) 1 (4.7) 19 14 (73.7)
4 41 6 (14.6) 4 (9.8) 12 3 (25.0)
5 38 2 (5.3) 1 (2.6) 38 3 (7.9)
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considering the active tuberculosis group and healthy indivi-
duals. These findings are in agreement with other results.
Although the sensitivity rate is not as high as desired for a
perfect diagnostic test, specificity values are very high. We
found that 53.6% of active and 25.0% of inactive tuberculosis
cases had IgG A60. These results are similar to or lower than
those of other authors, who found the rate of positivity to be
between 36% and 85% [16,22,25]. This may be because of the
population chosen or the criteria that these authors used for
diagnosis. According to our results, the IgG positivity rate was
significantly higher than in healthy individuals and in patients
with lung diseases other than tuberculosis. Our findings are
consistent with the results of Alifano et al [17] and Turneer and
Nerom [19].
In the present study, the sensitivity of A60 IgM antibody
was found to be 43.8%. The sensitivity value for this anti-
body was previously reported to be between 24% and 80%
[12,16,21,23,24]. This wide range may be explained by the time
of diagnosis, because IgM can be detected at the early stages of
tuberculosis and after a short period of time it decreases, while
IgG antibodies increase [23]. In our study, the specificity of
IgM was found to be 97.4%, which is a higher value than
the sensitivity. A60 IgM EIA with high specificity could be
used as a reliable test in the diagnosis of pulmonary tuberculosis
when the result is positive.
We found the positivity rates of IgA antibody to be 78.1%,
73.7% and 37.5% for the active, miliary and inactive tubercu-
losis cases, respectively. These values are in agreement
with the results of Gupta et al [21]. Our sensitivity and
specificity values according to the IgA test are 78.1% and
92.1%. To our knowledge, this is the first study to consider
IgA serologic testing against A60 in various cases of tuberculosis
in a Turkish population. Our results indicate that A60
IgA antibody seems to be a useful diagnostic test for active
tuberculosis cases.
The positivity rates of IgG, IgM and IgA for the miliary
tuberculosis group were 47.6%, 4.7% and 73.7%, respectively.
Very few data are currently available concerning the usefulness
of IgA A60 antibody testing in miliary tuberculosis cases. Zou
et al [16] and Gupta et al [21] searched for these antibodies in
miliary tuberculosis cases and reported the sensitivities of IgG as
76% and 91.6%, those of IgM as 50% and 45%, and those of IgA
as 88.4% and 54%. The specificity values were found to be over
90% for all antibodies. It can be concluded that IgG and IgA
A60 antibodies should be considered for miliary tuberculosis
cases which are difficult to diagnose and usually require invasive
procedures.
The positivity rates of the antibodies can be considered to be
relatively low when compared to the culture and smear posi-
tivity rates in group 1 (100% and 91%, respectively). However,
the detection of antibody response can be important, especially
in smear-negative cases, since antibody response is notTa
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statistically different between smear-negative and smear-posi-
tive cases. At the same time, the disadvantages of the classical
techniques mentioned above should be considered.
In our study, we found the rates of IgG, IgM and IgA A60
positivity to be 5.3%, 2.6% and 7.9% for the healthy individuals,
and 14.6%, 9.8% and 25.0% for the patients with various lung
diseases, respectively. The diagnosis of the patients who gave
false-positive results were pneumonia and lung carcinoma in the
group of non-tuberculous lung diseases. The rates of IgG A60
for these groups were found to be 0.38–23.8% and 6–55%,
respectively, in previous studies [16,17,20,22,23]. Zou et al [16]
reported two false-positive results for IgM and IgA antibodies;
however, they mentioned one false-positive case in the group of
healthy individuals. They also pointed out three instances of
false positivity among 205 patients with lung diseases other than
tuberculosis. Alifano et al [17] found similar false-positive
results. These results may be due either to subclinical infection
with environmental non-tuberculous mycobacteria that also
express A60, or to the presence in the host of commensal non-
pathogenic mycobacteria [26,27]. The dysregulation of the
humoral immune response might be another cause of non-
tuberculous disease [26]. Dhand et al [28] reported that BCG
and lung cancer cells shared common antigens, which could
explain the false positivity observed for patients with lung
cancer.
We conclude that measurement of antibodies against A60,
especially if molecular and new techniques for the diagnosis of
tuberculosis are not available, may be considered a useful
diagnostic tool in early active tuberculosis cases, as shown in
a Turkish population. IgM antibody against A60 with high
specificity could be used as a reliable test in the diagnosis of
pulmonary tuberculosis when the result is positive.
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Many patients with community-acquired pneumonia can be
treated on an outpatient basis, but a significant proportion of
patients require hospitalization for initiation of parenteral anti-
biotic therapy [1]. Patients with pneumonia may be converted
from parenteral antibiotic treatment to oral treatment after
3–5 days. Although outpatient parenteral treatment has been
shown to be effective in the therapy of community-acquired
pneumonia, early conversion to oral antibiotic treatment may
result in significantly fewer adverse events and reduction of
major costs. With the availability of newer oral b-lactam agents
with favorable pharmacokinetic and pharmacodynamic proper-
ties, the use of step-down therapy for lower respiratory tract
infections has increased in clinical medicine [2].
For most cases of community-acquired pneumonia requiring
hospitalization, the recommended regimens consist of a cepha-
losporin such as cefuroxime, cefotaxime or ceftriaxone, or a
penicillin plus a b-lactamase inhibitor with or without ery-
thromycin [1]. The most often isolated pathogenic bacteria are
Streptococcus pneumoniae, Haemophilus influenzae and Moraxella
catarrhalis. The recommended agents are active against these
pathogens.
Loracarbef, a synthetic b-lactam agent of the carbacephem
class for oral administration, has favorable pharmacokinetic,
pharmacodynamic and microbiological properties, which sug-
gests that this agent may be useful for early conversion from
parenteral treatment to oral treatment of community-acquired
pneumonia [3].
The most common and significant cause of disturbances in
the normal intestinal microflora is the administration of anti-
microbial agents [4]. When the number of microorganisms is
reduced during therapy, resistance to colonization is decreased,
which may lead to several unwanted effects. One is overgrowth
of already present microorganisms with natural resistance, such
as yeasts, which may cause systemic infections in immunocom-
promised patients, and Clostridium difficile, which may lead to
diarrhea and/or colitis. A second consequence is the establish-
ment of new resistant pathogenic bacteria, which may also
colonize other areas of the host. A third effect is the fact that
bacterial overgrowth also encourages the transfer of resistance
factors among bacteria. Several factors influence the extent to
which a given antimicrobial agent will reduce the normal
microflora. Predominant among these factors is the incomplete
absorption of agents perorally administered. Poorly absorbed
drugs can reach the colon in active form, where they suppress
susceptible microorganisms and disturb the ecological balance.
Antimicrobial drugs that are secreted in the bile or from the
intestinal mucosa also tend to affect the normal intestinal
microflora.
Loracarbef is approximately 90% absorbed from the gastro-
intestinal tract after oral administration, and only a minor impact
on the intestinal microflora has been reported [5,6]. In contrast,
parenteral ceftriaxone is excreted in the bile in high concen-
trations, resulting in major changes of the intestinal microflora
[7–9].
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